Pfizer Inc. (NYSE:PFE) Stock Has Consensus Target Price of $28.72

Pfizer Inc. (NYSE:PFE) has earned an average recommendation of “Hold” from the twenty-one analysts that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and five have given a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $28.72.

Several equities research analysts have recently commented on the company. BMO Capital Markets cut their price target on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. JPMorgan Chase & Co. increased their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 9th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, October 13th. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Finally, Bank of America dropped their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer has outperformed the broader market this year and is described as undervalued relative to its earnings potential. A possible rotation from technology stocks into healthcare could provide an additional catalyst, while the dividend remains attractive to income-focused investors. Pfizer’s Stock Is Finally Showing Signs of Life
• Positive Sentiment: Pfizer completed its Phase 2 MAGNETISMM-3 study of elranatamab, an oncology treatment candidate. Further details on the trial could influence expectations for Pfizer’s cancer-drug pipeline and future growth. Pfizer’s Elranatamab Trial Update
• Neutral Sentiment: Wells Fargo maintained a Hold rating on Pfizer, suggesting the current valuation may fairly reflect both the company’s income appeal and its operational risks. Pfizer Gets a Hold from Wells Fargo
• Neutral Sentiment: RBC Capital also reaffirmed its Hold rating. Investors are awaiting quarterly results for evidence that Pfizer’s non-oncology portfolio can offset vaccine-sales declines, pricing pressure and uneven demand. RBC Reaffirms Hold Rating
• Negative Sentiment: Pfizer’s dividend freeze has renewed concerns about cash-flow strength. Although the roughly 5.8% yield is appealing, analysis suggests the payout consumes a large share of available cash, raising the risk that income investors may question its long-term sustainability. Pfizer’s Dividend Freeze Raises Cash-Flow Questions

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in PFE. Retirement Wealth Solutions LLC boosted its holdings in Pfizer by 144.6% in the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 509 shares in the last quarter. Evolution Wealth Management Inc. increased its position in Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares during the period. Keb Asset Management LLC purchased a new position in shares of Pfizer during the 2nd quarter worth approximately $26,000. Field & Main Bank purchased a new position in shares of Pfizer during the 2nd quarter worth approximately $27,000. Finally, Global Trust Asset Management LLC lifted its holdings in shares of Pfizer by 126.7% in the 1st quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 650 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Down 0.4%

PFE opened at $29.45 on Thursday. The business has a 50 day moving average price of $28.05 and a two-hundred day moving average price of $26.57. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The company has a market cap of $167.86 billion, a PE ratio of 9.70, a P/E/G ratio of 2.01 and a beta of 0.32. Pfizer has a 52 week low of $23.62 and a 52 week high of $29.88.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The company had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period last year, the firm earned $0.78 EPS. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts anticipate that Pfizer will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 5.8%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is 226.32%.

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.